SILENCE THER. (SLN)

 

SLN Share PerformanceMore

52 week high130.00 05/10/16
52 week low71.88 03/05/17
52 week change -26.00 (-21.14%)
4 week volume556,958 30/05/17

Technical Insight

Login or Register to access technical insights.

Latest NewsMore

Result of AGM

RNS Number: 2062H Silence Therapeutics PLC 06 June 2017 Results of AGM 6 June 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that all of the resolutions proposed at the Annual General ...

Hiring of Chief Operating Officer

RNS Number: 7677G Silence Therapeutics PLC 01 June 2017 Hiring of Chief Operating Officer 1 June 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces the hiring of Torsten Hoffmann as Chief...

Silence Therapeutics expands intellectual property estate

Silence Therapeutics has announced a further step in the expansion of its chemical modification patent estate. Earlier in M...

Silence Continued Expansion of IP

RNS Number: 4723G Silence Therapeutics PLC 30 May 2017 Continued expansion of Intellectual Property - additional US patent application allowed for grant 30 May 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet m...

Silence Therapeutics expands intellectual property estate

Silence Therapeutics has announced a significant expansion of its chemical modification patent estate, and might consider ...

Significant Expansion of Intellectual Property

RNS Number: 1978F Silence Therapeutics PLC 16 May 2017 Significant expansion of Intellectual Property (March to May 2017) 16 May 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery, and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces a signific...

Silence Therapeutics schedules AGM

Silence Therapeutics has announced that the Annual General Meeting of the Company will be held on Friday 2 June. At 1:5...

Notice of AGM and Publication of Annual Report

RNS Number: 2075E Silence Therapeutics PLC 04 May 2017 Notice of AGM and publication of Annual Report 4 May 2017 Silence Therapeutics plc, AIM:SLN ("Silence" or "the Company") a leader in the discovery, delivery and development of novel RNA therapeutics for the treatment of serious diseases with unmet medical need, announces that its annual report an...

Fundamental DataMore

EPS-12.1
Dividend yield0 %

Equity Research (SLN)

edison investment research
Silence Therapeutics plc
13/04/2017
Edison Investment Research is terminating coverage on Silence Therapeutics (SLN). Please note you should no longer rely on any previous research or estimates for this company. All forecasts should...

Latest discussion posts More

  • Re: Slow decline.

    Hi, Totally agree and I am not sure why apart from just general lack of interest. The attached might help cheer you up a ...
    27-Apr-2017
    tallyfox
  • Slow decline.

    Feels like death by a thousand cuts at the moment. What's it going to take to reverse this decline?
    27-Apr-2017
    rikid

Users' HoldingsMore

Users who hold SILENCE THER. also hold..
LLOYDS GRP.33%
BP26%
TESCO21%
BARCLAYS19%
ROYAL BANK SCOT19%

Codes & Symbols

ISINGB00B9GTXM62
SymbolsSLN, LSE:SLN, SLN.L, SLN:LN, LON:SLN, XLON:SLN